Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Net Margin: 2015-2020

Historic Net Margin for Outlook Therapeutics (OTLK) over the last 6 years, with Sep 2020 value amounting to 52,133.97%.

  • Outlook Therapeutics' Net Margin rose 5230922.00% to 52,133.97% in Q3 2020 from the same period last year, while for Sep 2020 it was 2,782.50%, marking a year-over-year increase of 322491.00%. This contributed to the annual value of 2,387.32% for FY2024, which is 5712.00% up from last year.
  • Outlook Therapeutics' Net Margin amounted to 52,133.97% in Q3 2020, which was up 7,571.28% from 679.60% recorded in Q2 2020.
  • In the past 5 years, Outlook Therapeutics' Net Margin ranged from a high of 52,133.97% in Q3 2020 and a low of -6,300.21% during Q4 2016.
  • Moreover, its 3-year median value for Net Margin was -787.71% (2019), whereas its average is 4,621.66%.
  • Its Net Margin has fluctuated over the past 5 years, first slumped by 514,114bps in 2016, then spiked by 5,230,922bps in 2020.
  • Quarterly analysis of 5 years shows Outlook Therapeutics' Net Margin stood at -6,300.21% in 2016, then spiked by 400,373bps to -2,296.48% in 2017, then surged by 136,988bps to -926.60% in 2018, then skyrocketed by 401,824bps to 3,091.65% in 2019, then soared by 5,230,922bps to 52,133.97% in 2020.
  • Its Net Margin stands at 52,133.97% for Q3 2020, versus 679.60% for Q2 2020 and 2,508.02% for Q1 2020.